ABBVAbbVieRunning, no new patients
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
Unresectable Metastatic Colorectal Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 280 (planned)
- Started
- Nov 12, 2023
- Main results expected
- Dec 2026
- Fully finished
- Dec 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants with Objective Response
Measured over: Up to 24 Weeks
Progression Free Survival (PFS)
Measured over: Up to 11 Months
Number of Participants with Adverse Events (AEs)
Measured over: Up to 3 Years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06107413 · record last updated 2025-12-12 · checked 2026-11-09 15:47 UTC